Literature DB >> 22213733

Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis.

Russell Steele1, Marie Hudson, Ernest Lo, Murray Baron.   

Abstract

OBJECTIVE: To develop a clinical decision rule to predict the presence of interstitial lung disease (ILD) in systemic sclerosis (SSc; scleroderma) and to estimate the prevalence of SSc-ILD.
METHODS: Patient data were extracted from the Canadian Scleroderma Research Group registry. Three algorithms for the clinical decision rule were considered based on lung auscultation, chest radiography (CXR), and % predicted forced vital capacity (FVC). High-resolution computed tomography (HRCT) scans were used as the gold standard to determine the diagnostic properties of the 3 algorithms. Multiple imputation was used to impute HRCT data when missing, thereby avoiding bias due to differential referral for HRCT.
RESULTS: This study included 1,168 patients. Of the patients with HRCT scans, 65% had evidence of ILD, compared to 26% by physical examination and 22% by CXR. The FVC of those who did not have HRCT was 8.8% greater than those who did (95% confidence interval [95% CI] 6.0-11.6%). Algorithm A, which identified the presence of ILD based on crackles on lung auscultation and/or findings on CXR, had a likelihood ratio of 3.9, compared to 3.2 for Algorithm B (which included patients with FVC <70%) and 2.2 for Algorithm C (which included patients with FVC <80%). The prevalence of ILD in the cohort was estimated to be 52% (95% CI 46-59%).
CONCLUSION: We developed a simple clinical decision rule to predict SSc-ILD with good test characteristics. The prevalence of ILD in a large, unselected SSc cohort was estimated to be 52%.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2012        PMID: 22213733     DOI: 10.1002/acr.21583

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  39 in total

1.  Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality.

Authors:  Nicolas Richard; Marie Hudson; Mianbo Wang; Geneviève Gyger; Susanna Proudman; Wendy Stevens; Mandana Nikpour; Murray Baron
Journal:  Rheumatology (Oxford)       Date:  2019-04-01       Impact factor: 7.580

Review 2.  Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.

Authors:  Aryeh Fischer; Jörg Distler
Journal:  Clin Rheumatol       Date:  2019-08-19       Impact factor: 2.980

3.  Interstitial lung disease in South Africans with systemic sclerosis.

Authors:  Philippa Ashmore; Mohammed Tikly; Michelle Wong; Claudia Ickinger
Journal:  Rheumatol Int       Date:  2017-11-28       Impact factor: 2.631

4.  Immunosuppression for interstitial lung disease in systemic sclerosis - novel insights and opportunities for translational research.

Authors:  Marie Hudson; Russell Steele; Murray Baron
Journal:  J Cell Commun Signal       Date:  2012-08-03       Impact factor: 5.782

5.  Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.

Authors:  Sabrina Hoa; Sasha Bernatsky; Russell J Steele; Murray Baron; Marie Hudson
Journal:  Rheumatology (Oxford)       Date:  2020-05-01       Impact factor: 7.580

Review 6.  Clinical Trial Design Issues in Systemic Sclerosis: an Update.

Authors:  Jessica K Gordon; Robyn T Domsic
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

7.  Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis.

Authors:  Xiaochun Liu; Maureen D Mayes; Filemon K Tan; Minghua Wu; John D Reveille; Brock E Harper; Hilda T Draeger; Emilio B Gonzalez; Shervin Assassi
Journal:  Arthritis Rheum       Date:  2013-01

8.  Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis.

Authors:  Carolina Mejia Otero; Shervin Assassi; Marie Hudson; Maureen D Mayes; Rosa Estrada-Y-Martin; Claudia Pedroza; Tingting W Mills; Jennifer Walker; Murray Baron; Wendy Stevens; Susanna M Proudman; Mandana Nikpour; Sonal Mehra; Mianbo Wang; Marvin J Fritzler
Journal:  J Rheumatol       Date:  2017-04-01       Impact factor: 4.666

9.  Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.

Authors:  Kimberly Showalter; Aileen Hoffmann; Gerald Rouleau; David Aaby; Jungwha Lee; Carrie Richardson; Jane Dematte; Rishi Agrawal; Rowland W Chang; Monique Hinchcliff
Journal:  J Rheumatol       Date:  2018-10-01       Impact factor: 4.666

Review 10.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.